Table 2.
CSF concentration of markers in patients treated with memantine versus the control group.
| Marker | 3-NT | MDA | GSH | NP-SH | NP-SS-NP |
|---|---|---|---|---|---|
| nmol/ml | nmol/ml | nmol/ml | µg/ml | µg/ml | |
| Control AD patients | 0.092 ± 0.037 | 9.043 ± 3.414 | 0.354 ± 0.040 | 0.986 ± 0.099 | 3.011 ± 4.469 |
| AD patients treated with memantine | 0.075 ± 0.026 | 9.349 ± 2.020 | 0.426 ± 0.192 | 1,529 ± 0.543 | 3.326 ± 1.434 |
| * | * | * |
*Indicates a statistically significant difference (Mann–Whitney U test, p ≤ 0.05). Concentrations of 3-NT, MDA, and GSH are in nmol/ml; concentrations of NP-SH and NP-SS-NP are in μg/ml. The mean CSF level of memantine (n = 22) in the treated group was 65.33 ± 9.4 ng/ml.